ArticleAmerican journal of translational research2024
Transurethral resection of bladder tumor with Bacille Calmette-Guerin intravesical instillation for HRNMIBC and factors influencing recurrence.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effectiveness of combining transurethral resection of bladder tumor (TURBT) with Bacille Calmette-Guerin (BCG) intravesical instillation in treating high-risk non-muscle invasive bladder cancer (HRNMIBC).
methodsWe retrospectively reviewed the clinical data from 118 HRNMIBC patients treated at Tongren Hospital between March 2020 and June 2022. The patients were categorized into two groups based on their treatment regimen: the control group (n=60) which received regular pirarubicin intravesical instillation, and the observation group (n=58) which received additional BCG intravesical instillation alongside pirarubicin. All patients underwent TURBT. Postoperative follow-up included monitoring recurrence and adverse reactions. Quality of life was assessed for both groups before and after treatment. Peripheral blood T lymphocyte subsets and immunoglobulin levels were measured pre- and post-instillation. Patients were further classified into recurrence and non-recurrence groups to analyze factors influencing HRNMIBC recurrence.
resultsThe observation group exhibited a recurrence rate of 22.41% (13/58), notably lower than the 41.66% (25/60) in the control group (P<0.05). Both groups showed improved postoperative scores in somatic, emotional, social, cognitive, and role functions compared to preoperative scores, with the observation group demonstrating significantly higher scores across all domains (all P<0.05). Post-instillation, CD4+, CD4+/CD8+, Immunoglobulin M (IgM), Immunoglobulin G (IgG), and Immunoglobulin A (IgA) levels were elevated in both groups relative to pre-instillation levels, whereas CD8+ levels were reduced. The observation group showed significantly higher levels of CD4+, CD4+/CD8+, IgM, IgG, and IgA, and lower levels of CD8+ compared to the control group following instillation (all P<0.05). Univariate analysis revealed that tumor number, stage, grade, and primary tumor status were all significantly associated with HRNMIBC recurrence (all P<0.05). Multivariate logistic regression further identified tumor number, stage, grade, and primary status as independent predictors of HRNMIBC recurrence (all P<0.05).
conclusionThe combination of TURBT with pirarubicin and BCG intravesical instillation significantly lowers the recurrence rate in HRNMIBC patients and enhances both quality of life and immune function recovery. Independent factors affecting HRNMIBC recurrence include tumor number, stage, grade, and primary tumor status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.